Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility of Evaluating XSTAT Use in the Prehospital Setting (PhoXSTAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04663087
Recruitment Status : Not yet recruiting
First Posted : December 10, 2020
Last Update Posted : March 8, 2022
Sponsor:
Information provided by (Responsible Party):
Jan O. Jansen, University of Alabama at Birmingham

Brief Summary:
This study evaluates the prehospital use of the XSTAT device to control bleeding in junctional wounds. Participants will be randomized to the use of XSTAT versus standard care.

Condition or disease Intervention/treatment Phase
Shock, Hemorrhagic Injury Penetrating Hemorrhage Device: XSTAT Other: Standard of Care Not Applicable

Detailed Description:

The XSTAT® device injects small, rapidly-expanding cellulose sponges into the wound cavity using a syringe-like delivery system. In the wound, XSTAT® sponges expand and swell to fill the wound cavity, within 20 seconds of contact with blood, facilitating compression of bleeding structures. XSTAT® can be applied through skin wounds. The system can readily access deep vascular structures. While rapidly hemostatic, the hemostatic sponges are also relatively easy to remove. In the setting of junctional bleeding, XSTAT® may allow for hemostatic pressure generation from within the wound tract rather than from external compression (as with a tourniquet or manual compression).

Hemorrhage should be controlled as early as possible, ideally before reaching a trauma center or medical treatment facility. Given its small size, low weight, and ease of application, the XSTAT® device is well-suited for prehospital use, in both the civilian and military setting, and this is probably where the device's applicability lies.

The investigators anticipate that a full-scale trial will be conducted based on the questions this pilot study addresses, including the following:

  1. the number of penetrating junctional zone injuries encountered in the prehospital civilian setting.
  2. the feasibility of randomizing patients in the prehospital setting.
  3. usability.
  4. safety.
  5. validation of the proposed primary outcome of an efficacy trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Randomized Clinical Trial of the XSTAT Hemostatic Device in the Prehospital Setting
Estimated Study Start Date : August 1, 2022
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : August 2023

Arm Intervention/treatment
Experimental: Treatment with XSTAT
Participants randomized to the treatment arm will be treated using the study device - XSTAT.
Device: XSTAT
XSTAT application will follow the manufacturer's guidance, with injection into bleeding junctional wounds. A sufficient number of sponges are used to fill the injury void. Repeated XSTAT application is performed in the event of persistent bleeding. The trial packs will contain two devices.
Other Name: XSTAT 12

Standard Care
Participants assigned to the control group receive standard prehospital care, consisting of direct pressure/dressings.
Other: Standard of Care
As currently provided by EMS services




Primary Outcome Measures :
  1. Incidence of patients with hemorrhage from junctional wounds [ Time Frame: Through 29 months ]
    The investigators will track the number of junctional wounds that are treated by participating EMS personnel versus the number of participants who were enrolled in this study. This will help the investigators understand how many wounds of this type happen, and how many would possibly benefit from the use of the XSTAT device.

  2. Record blood lactate level result [ Time Frame: Baseline - on admission ]
    Record results of routine test

  3. Record base deficit result [ Time Frame: Baseline - on admission ]
    Record results of routine test

  4. Record hemoglobin/hematocrit result [ Time Frame: Baseline - on admission ]
    Record results of routine test

  5. Record platelet count result [ Time Frame: Baseline - on admission ]
    Record results of routine test

  6. Record prothrombin time result [ Time Frame: Baseline - on admission ]
    Record results of routine test

  7. Record international normalized ratio (INR) result [ Time Frame: Baseline - on admission ]
    Record results of routine test

  8. Record activated partial thromboplastin time (APTT) / ratio result [ Time Frame: Baseline - on admission ]
    Record results of routine test

  9. Record activated partial thromboplastin time (APTT) result [ Time Frame: Baseline - on admission ]
    Record results of routine test

  10. Record thromboelastograph (TEG) result if available [ Time Frame: Baseline - on admission ]
    Record results of routine test

  11. Record thromboelastogram (ROTEM) result if available [ Time Frame: Baseline - on admission ]
    Record results of routine test

  12. Ease of use of XSTAT device by EMS personnel [ Time Frame: From baseline to 29 months (enrollment phase) ]
    To answer the question "Is the XSTAT device easy to use in the prehospital setting," the study case report forms capture whether EMS personnel found the device easy to insert into a wound, whether the sponges were expelled from the device easily, and whether the EMS personnel were satisfied or dissatisfied with the XSTAT device itself.

  13. Sponge removal: surgeon opinion of ease of removal, time required to remove sponges, use of x-rays, whether surgeon was satisfied or dissatisfied with the XSTAT device. [ Time Frame: From baseline to 29 months (enrollment phase) ]
    Case report forms capture whether sponges were easy to remove, how much time was required to remove the sponges, whether x-rays were obtained to ensure that no sponges were left in the body, and whether the surgeon was satisfied or dissatisfied with the XSTAT device

  14. Adverse events from use of XSTAT device [ Time Frame: Randomization through first 7 days, unless discharged earlier ]
    All AEs, whether expected or unexpected will be recorded and reviewed throughout the trial. Each AE will be reported separately, with a description of the event, whether it was related to the device, whether it was serious, and whether it was expected or unexpected.

  15. Survival at 30 days [ Time Frame: Hospital admission through 30 days ]
    Time of death, or survival at 30 days will be recorded



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥15 years or estimated body weight ≥50 kg.
  2. Penetrating junctional injury (femoral or axillary), with i. visible bleeding ii. too proximal to be controlled with a tourniquet
  3. Patient will be taken to participating level I trauma center, directly from the scene

Exclusion Criteria:

  1. Prisoners, children <15 years old, known pregnant patients.
  2. Patients receiving chest compressions (prior to XSTAT® use).
  3. Patients with an opt-out bracelet.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04663087


Contacts
Layout table for location contacts
Contact: Karen N Brown, MSHA 205-975-2393 karenbrown@uabmc.edu
Contact: Shannon Stephens, EMTP, CCEMTP 205-934-5890 swstephens@uabmc.edu

Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Layout table for investigator information
Principal Investigator: Jan Jansen, MBBS, PhD The University of Alabama at Birmingham
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jan O. Jansen, Primary Investigator, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT04663087    
Other Study ID Numbers: IRB-300003647
First Posted: December 10, 2020    Key Record Dates
Last Update Posted: March 8, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Jan O. Jansen, University of Alabama at Birmingham:
hemorrhagic shock
hemostatic sponge
penetrating injury
junctional wounds
prehospital
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemorrhage
Shock, Hemorrhagic
Wounds, Penetrating
Pathologic Processes
Shock
Wounds and Injuries